Prompted by the previous findings demonstrating the role of the enzymes regulating sphingosine-1-phosphate (S1P) and ceramide metabolism as mediators of chemoresistance in colon cancer [10,11,12] and based on an earlier observation from the study in BRAFV600E mutated melanoma which revealed altered ceramide/S1P ratio in vemurafenib-resistant cells [13], we sought to investigate the possible involvement of the key regulators of S1P and ceramide turnover and signalling in acquired resistance to vemurafenib in BRAF mutated colon cancer cells. Here, BRAF is linked to malignant colon neoplasm.